4.9(top 5%)
impact factor
6.8K(top 5%)
papers
91.9K(top 5%)
citations
94(top 5%)
h-index
5.1(top 10%)
extended IF
8.8K
all documents
100.5K
doc citations
136(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Epidemiological trends in skin mycoses worldwideMycoses2008970
2Molecular diagnostics of clinical strains of filamentous BasidiomycetesMycoses1998492
3COVID‐19 associated pulmonary aspergillosisMycoses2020452
4Hydrolytic enzymes as virulence factors of Candida albicansMycoses2005432
5The changing face of epidemiology of invasive fungal disease in EuropeMycoses2009359
6The Clinical Pharmacokinetics of Itraconazole: An OverviewMycoses1989346
7Antifungal drug resistance among Candida species: mechanisms and clinical impactMycoses2015332
8High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase geneMycoses2018256
9An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospitalMycoses2018254
10Trichosporon on humans: a practical accountMycoses1994248
11Antifungal activity of plant extracts against dermatophytesMycoses1999229
12Aspergillus flavus: an emerging non‐fumigatus Aspergillus species of significanceMycoses2009227
13Epidemiology of tinea capitis in Europe: current state and changing patternsMycoses2007224
14Onychomycosis, Tinea Pedis and Tinea Manuum Caused by Non‐Dermatophytic Filamentous Fungi Nicht‐Dermatophyten‐Fadenpilze als Erreger von Onychomykosen, Tinea pedis und Tinea manuumMycoses1989212
15Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20‐year autopsy studyMycoses2013205
16Chromoblastomycosis: clinical and mycologic experience of 51 casesMycoses2001199
17COVID‐19‐associated mucormycosis: An updated systematic review of literatureMycoses2021195
18MucormycosesMycoses2001178
19The current Indian epidemic of superficial dermatophytosis due to Trichophyton mentagrophytes—A molecular studyMycoses2019178
20Antifungal Prophylaxis with Itraconazole in Prolonged Neutropenia: Correlation with Plasma LevelsMycoses1989174
21Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosisMycoses2003170
22In vitro efficacy of 75 essential oils against Aspergillus nigerMycoses2006170
23Histoplasmosis: a review for clinicians from non-endemic areasMycoses2006166
24In vitro antimicrobial activity of olive leaves. Antimikrobielle Wirksamkeit von Olivenblattern in vitroMycoses2003164
25High prevalence of foot diseases in Europe: results of the Achilles ProjectMycoses2003163
26Fungal keratitis: An overview of clinical and laboratory aspectsMycoses2018162
27Mucormycosis in India: unique featuresMycoses2014159
28The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosisMycoses2021157
29Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entityMycoses2021155
30Candida auris—the growing menace to global healthMycoses2019153
31Phospholipase and protease activities in clinical Candida isolates with reference to the sources of strainsMycoses2002152
32A More Sophisticated Method of Determining the Fungicidal Effect of Water‐Insoluble Preparations with a Cell Harvester, Using Miconazole as an Example./Eine verbesserte Methode zur Bestimmung der Fungizidie von wasserunlöslichen Präparaten mit Hilfe eines Zellerntegerätes am Beispiel von MiconazolMycoses1988152
33Antifungal activity of propolis on different species ofCandidaMycoses2001151
34Use of Punica granatum as an antifungal agent against candidosis associated with denture stomatitis. Verwendung von Punica granatum als Antimykotikum gegen Candidose in Verbindung mit Zahnprothesen-StomatitisMycoses2003148
35Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilmsMycoses2012148
36Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survivalMycoses1999147
37Epidemiology and molecular mechanisms of antifungal resistance in Candida and AspergillusMycoses2016147
38COVID‐19‐associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID‐19 pneumonia: An observational study from PakistanMycoses2020147
39Alarming India‐wide phenomenon of antifungal resistance in dermatophytes: A multicentre studyMycoses2020147
40ECMM/ISHAM recommendations for clinical management of COVID‐19 associated mucormycosis in low‐ and middle‐income countriesMycoses2021147
41High prevalence of the neurotropeExophiala dermatitidisand related oligotrophic black yeasts in sauna facilitiesMycoses2002145
42Detection of Aspergillus galactomannan antigen in foods and antibioticsMycoses1997143
43Dematiaceous fungiMycoses2007143
44Inhibitory effect of essential oils on apical growth of Aspergillus fumigatus by vapour contactMycoses2000142
45Antifungal susceptibility of Candida albicans in biofilmsMycoses2012141
46Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazoleMycoses1999140
47Temporal events in the intravenous challenge model for experimental Candida albicans infections in female miceMycoses2005139
48The Treatment of Aspergillosis and Aspergilloma with Itraconazole, Clinical Results of an Open International Study (1982 ‐ 1987)/Die Behandlung der Aspergillose und des Aspergilloms mit Itraconazol, Klinische Ergebnisse einer offenen internationalen Studie (1982 ‐ 1987)Mycoses1988139
49Defining breakthrough invasive fungal infection–Position paper of the mycoses study group education and research consortium and the European Confederation of Medical MycologyMycoses2019139
50Performance of MALDITOF MS platforms for fungal identificationMycoses2016137